A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

Table 2

Mean (and SD) doses and blood levels of sirolimus and calcineurin inhibitors in subjects receiving these medications at specified time relative to conversion to sirolimus.

	Conversion	Month 3	Month 6	Year 1	Year 2
All subjects (𝑛=484)
Sirolimus dose (mg/d)	4.3 ± 3.8	2.9 ± 2.1	2.8 ± 1.6	2.6 ± 1.5	2.3 ± 1.1
Sirolimus level (μg/L)	5.4 ± 5.5	10.1 ± 4.6	9.3 ± 4.0	9.0 ± 3.8	8.5 ± 2.9
Tacrolimus dose (mg/d)	6.0 ± 4.1	5.4 ± 3.3	5.3 ± 2.8	5.3 ± 3.6	4.5 ± 2.2
Tacrolimus level (μg/L)	7.3 ± 3.6	6.7 ± 3.8	5.8 ± 3.2	5.8 ± 2.5	5.0 ± 2.2
Cyclosporine dose (mg/d)	188 ± 183	181 ± 111	154 ± 107	128 ± 74	167 ± 107
Cyclosporine level (μg/L)	194 ± 181	220 ± 129	186 ± 101	158 ± 91	159 ± 91
Converted early (𝑛=187)
Sirolimus dose (mg/d)	4.3 ± 2.9	3.2 ± 2.6	2.8 ± 1.6	2.7 ± 1.8	2.1 ± 0.7
Sirolimus level (μg/L) < 1 yr	8.4 ± 5.9	10.4 ± 4.6	9.7 ± 4.0	9.0 ± 4.0	8.4 ± 3.1
Tacrolimus dose (mg/d)	7.5 ± 5.7	6.9 ± 4.4	6.4 ± 3.5	7.0 ± 4.7	5.5 ± 2.7
Tacrolimus level (μg/L)	8.7 ± 4.0	7.1 ± 3.8	6.5 ± 3.8	6.1 ± 2.5	6.0 ± 3.2
Cyclosporine dose (mg/d)	283 ± 309	220 ± 148	186 ± 155	130 ± 92	NS
Cyclosporine level (μg/L)	270 ± 237	204 ± 137	120 ± 60	99 ± 63	88 ± 46
Converted late (𝑛=297)
Sirolimus dose (mg/d)	4.3 ± 4.4	2.7 ± 1.7	2.7 ± 1.6	2.6 ± 1.3	2.4 ± 1.2
Sirolimus level (μg/L) > 1 yr	4.1 ± 4.8	10.5 ± 4.6	9.7 ± 4.0	9.0 ± 4.0	8.4 ± 3.1
Tacrolimus dose (mg/d)	4.7 ± 2.1	4.5 ± 2.0	4.5 ± 1.8	4.1 ± 1.9	4.0 ± 1.7
Tacrolimus level (μg/L)	6.1 ± 2.6	6.3 ± 3.8	5.3 ± 2.7	5.6 ± 2.5	4.4 ± 1.0
Cyclosporine dose (mg/d)	157 ± 99	150 ± 56	140 ± 79	128 ± 72	167 ± 107
Cyclosporine level (μg/L)	184 ± 172	225 ± 127	120 ± 66	99 ± 63	88 ± 46